October 29, 2024
Statement from TAG’s TB Project on Today’s WHO Global TB Report Release
Statement / Press
Treatment Action Group (TAG) is deeply concerned by the reported decrease in domestic funding for tuberculosis (TB) services announced today in the World Health Organization’s 2024 Global Tuberculosis Report.
October 15, 2024
Research Toward a Cure Trials
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).
October 8, 2024
Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short
Statement / Press
TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.
September 25, 2024
Statement on the UN High Level Meeting on Antimicrobial Resistance Final Draft Political Declaration
Statement / Press
Treatment Action Group (TAG) congratulates Malta and Barbados, co-facilitators, and all United Nations (UN) Member States participating in the High-Level Meeting on Antimicrobial Resistance (AMR) upon the publication of the final draft of the Political Declaration.
September 16, 2024
2024 Research in Action Awards Celebrate Leaders in Global Health Activism Who Exemplify TAG’s Mission
Statement / Press
Treatment Action Group’s (TAG) most important fundraising event of the year is the Research in Action Awards, which honor the best and brightest activists, researchers, leaders, and scientists whose work has been integral in ending HIV, tuberculosis (TB), and hepatitis C (HCV).
August 14, 2024
Treatment Action Group Calls for Coordinated, Fully Funded Global Response to Mpox Emergency
Statement / Press
Treatment Action Group (TAG) supports the World Health Organization (WHO) in declaring the renewed outbreak of mpox a public health emergency of international concern.
July 25, 2024
TAG Calls for Universal Access to Innovative HCV Testing to End the Disease by 2030
Statement / Press
This World Hepatitis Day, July 28, we are better positioned than ever to end hepatitis C Virus (HCV) as a pandemic.
July 25, 2024
Three New Members Elected to TAG’s Board of Directors
Statement / Press
Treatment Action Group (TAG) elected three new members to its Board of Directors in May 2024. Board President Ivy Kwan Arce said, “TAG is reinvigorating its Board in alignment with our vision, mission, and values.
July 18, 2024
2024 Pipeline Report
Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
July 17, 2024
2023 Annual Report
Publication
We’re pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.
June 26, 2024
Call For New Global TB CAB Members
On behalf of the Global Tuberculosis Community Advisory Board (TB CAB), we’re excited to announce a call for new member applications.
June 26, 2024
TAG Calls on Danaher to Drop the Prices of GeneXpert Tests and Make the Cost Audit Public
Statement / Press
Treatment Action Group (TAG) calls on Danaher to lower the price of GeneXpert tests for tuberculosis (TB) and other diseases to $5 each in accordance with publicly available evidence of the cost of manufacturing and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.
June 20, 2024
An Open Letter to Médecins Sans Frontières — Urgent Call to Reverse the Devastating Decision to Shutter the MSF Access Campaign
Letter / Comment
TAG’s emergency plea to our allies at MSF to preserve its life-saving and world-changing MSF Access Campaign (Campaign for Access to Essential Medicines) — we need them now more than ever!
June 20, 2024
Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions
Statement / Press
Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.
June 11, 2024
Frequently Asked Questions on Microarray Patches (MAPs)
Publication
Microarray patches (MAPs) are arrays of microneedles that stick to your skin like a bandage, offering a noninvasive mechanism for drug administration.
May 30, 2024
Comments Delivered at the WHO Director-General’s TB Vaccine Accelerator Council
Letter / Comment
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 2nd meeting of the WHO Director-General’s TB Vaccine Accelerator Council in Geneva Switzerland.
May 22, 2024
Treatment Action Group Calls on NY City Council to Override and Mayor Adams to Reverse Egregious Cuts to New York City HIV Funding
Statement / Press
In response to disheartening news of the proposed $5.3 million cut in HIV/AIDS funding by the Adams administration, we at Treatment Action Group (TAG) express our resolute opposition, in solidarity with our partner organizations that would be harmed by the egregious, unconscionable cuts to HIV services and programs in New York City.
May 17, 2024
TAG Comments at UN High-Level Meeting on Antimicrobial Resistance Hearing
Letter / Comment
TAG delivered an intervention at the UN High-Level Meeting on Antimicrobial Resistance (AMR) Multistakeholder Hearing, calling on member states to incorporate drug-resistant TB (DR-TB) in the political declaration as a key component of AMR response.
May 15, 2024
TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing
Webinar / Presentation
On May 15, 2024, TAG hosted this webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.
May 13, 2024
Comments In Regard to NIAID’S Strategic Plan, May 2024
Letter / Comment
Treatment Action Group submitted comments in response to “Request for Information (RFI): Inviting Comments and Suggestions on NIAID’s Strategic Plan” highlighting the organization’s key priorities across the NIAID portfolio.
May 10, 2024
An Activist’s Guide to Rifapentine – TB Preventive Treatment: 3HP and 1 HP
Publication
Rifapentine, an off-patent drug that’s been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.
May 10, 2024
Director of Development
Treatment Action Group (TAG) seeks a dynamic, motivated, and skilled individual to become its Director of Development supporting the organization as it continues to grow.
May 9, 2024
Community Engagement on Microarray Patches
Webinar / Presentation
TAG hosted this May 31 webinar on the growing pipeline of microarray patches (MAPs) for various infectious diseases treatment and immunization.
May 8, 2024
Treatment Action Group Welcomes Two New Board Members
Statement / Press
Treatment Action Group (TAG) is pleased to announce that two new members have been elected to the Board of Directors, Ama Burnham and Dr. Stefan V. Goldberg.
May 7, 2024
Going Behind the Scenes at TAG
Follow along with one of our staff members on a typical day, and you’ll see the difference you make as a TAG donor and partner.